Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented Paroxysmal Atrial Fibrillation (PAF): PAF diagnosis, 2 episodes of PAF within the last 2 months, at least 1 episode of PAF must be documented~* Age 18-75~* Documented Effectiveness Failure of one (1) AF drug~* Willing to be randomized to either group and do full 12 month follow-up~* Able to follow standardized AF drug protocol~Exclusion Criteria:~* Any cardioversion within 3 months or more than 2 within 2 years~* Amiodarone within 6 months~* LA size \> 5.0cm~* Previous LA ablation/surgery, structural heart disease, heart failure class III or IV~* Hypertrophic cardiomyopathy, Mitral prosthesis~* Unstable angina, uncontrolled hyperthyroidism~* Stroke or TIA within 6 months, MI within 2 months, cardiac surgery within 3 months~* Thrombocytosis, thrombocytopenia~* Any condition contraindicating chronic anticoagulation~* EF \<40%~* Pregnancy~* Life expectancy \<1year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): Experimental subjects received cryoablation intended to isolate the pulmonary veins and ablate arrhythmia foci. If necessary, experimental subjects were allowed a previously failed Study Atrial Fibrillation Drug (AF Drug).
- Control (Type: ACTIVE_COMPARATOR): Control Subjects were treated with an AF Drug (flecainide, propafenone, or sotalol) that they had not previously failed.

Based on this trial design, predict the completion outcome and termination type (if applicable).